Page last updated: 2024-08-24

ibandronic acid and anastrozole

ibandronic acid has been researched along with anastrozole in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R	1
Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L	1

Reviews

1 review(s) available for ibandronic acid and anastrozole

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for ibandronic acid and anastrozole

Article	Year
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Nitriles; Placebos; Triazoles	2008
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. European journal of cancer (Oxford, England : 1990), 2019, Volume: 108 Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method	2019

Article

Year

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19

Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Nitriles; Placebos; Triazoles

2008

Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.

European journal of cancer (Oxford, England : 1990), 2019, Volume: 108

Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method

2019